Related Experiment Video
Updated: Feb 25, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Nonencapsidated 5' Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by
Marie Mura1,2, Chantal Combredet1, Valérie Najburg1
1Unité de Génomique Virale et Vaccination, Institut Pasteur, CNRS UMR-3569, Paris, France.
Abstract:
Attenuated measles virus (MV) is one of the most effective and safe vaccines available, making it an attractive candidate vector for preventing other infectious diseases. Yet the great capacity of this vaccine still needs to be understood at the molecular level. MV vaccine strains have different type I interferon (IFN)-inducing abilities that partially depend on the presence of 5' copy-back defective interfering genomes (DI-RNAs). DI-RNAs are pathogen-associated molecular patterns recognized by RIG-I-like receptors (RLRs) (RIG-I, MDA5, and LGP2) that activate innate immune signaling and shape the adaptive immune response. In this study, we characterized the DI-RNAs produced by various modified recombinant MVs (rMVs), including vaccine candidates, as well as wild-type MV. All tested rMVs produced 5' copy-back DI-RNAs that were different in length and nucleotide sequence but still respected the so-called "rule of six." We correlated the presence of DI-RNAs with a larger stimulation of the IFN-β pathway and compared their immunostimulatory potentials. Importantly, we revealed that encapsidation of DI-RNA molecules within the MV nucleocapsid abolished their immunoactive properties. Furthermore, we identified specific interactions of DI-RNAs with both RIG-I and LGP2 but not MDA5. Our results suggest that DI-RNAs produced by rMV vaccine candidates may indeed strengthen their efficiency by triggering RLR signaling.IMPORTANCE Having been administered to hundreds of millions of children, the live attenuated measles virus (MV) vaccine is the safest and most widely used human vaccine, providing high protection with long-term memory. Additionally, recombinant MVs carrying heterologous antigens are promising vectors for new vaccines. The great capacity of this vaccine still needs to be elucidated at the molecular level. Here we document that recombinant MVs produce defective interfering genomes that have high immunostimulatory properties via their binding to RIG-I and LGP2 proteins, both of which are cytosolic nonself RNA sensors of innate immunity. Defective interfering genome production during viral replication should be considered of great importance due to the immunostimulatory properties of these genomes as intrinsic adjuvants produced by the vector that increase recognition by the innate immune system.
Insights
Measles virus (MV) defective interfering RNAs (DI-RNAs) enhance vaccine efficacy by stimulating innate immunity through RIG-I-like receptors. Encapsidation inactivates DI-RNAs, but their presence boosts immune response, acting as intrinsic adjuvants.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Live attenuated measles virus (MV) is a safe and effective vaccine, a promising vector for other diseases.
- MV vaccine strains' varying type I interferon (IFN)-inducing abilities are linked to 5' copy-back defective interfering RNAs (DI-RNAs).
- DI-RNAs are pathogen-associated molecular patterns recognized by RIG-I-like receptors (RLRs), activating innate immunity.
Purpose of the Study:
- To characterize DI-RNAs produced by various modified recombinant MVs (rMVs) and wild-type MV.
- To correlate DI-RNA presence with IFN-β pathway stimulation and compare immunostimulatory potentials.
- To investigate DI-RNA interactions with RLRs and the effect of encapsidation on their immunoactivity.
Main Methods:
- Characterization of 5' copy-back DI-RNAs from different rMVs and wild-type MV.
- Correlation analysis between DI-RNA presence and IFN-β pathway activation.
- Assessment of DI-RNA immunostimulatory potential and interaction with RIG-I, MDA5, and LGP2.
Main Results:
- All tested rMVs produced 5' copy-back DI-RNAs with varied lengths and sequences, adhering to the 'rule of six'.
- DI-RNA presence correlated with enhanced IFN-β pathway stimulation.
- Encapsidation of DI-RNAs within the MV nucleocapsid abolished their immunoactive properties; DI-RNAs interacted specifically with RIG-I and LGP2, but not MDA5.
Conclusions:
- DI-RNAs produced by rMV vaccine candidates possess significant immunostimulatory properties.
- DI-RNAs act as intrinsic adjuvants by triggering RLR signaling, potentially enhancing rMV vaccine efficiency.
- Understanding DI-RNA-RLR interactions is crucial for developing more potent recombinant MV vaccines.
Related Concept Videos
Viral Recombination
Retroviruses
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
Viruses with RNA Genomes
Leaky Scanning
DNA Bacteriophages

